Experts urge flexibility over heart device studies

09/21/2007 |

A panel of experts advised the FDA to be flexible on restrictions overseeing the clinical trials of devices for the treatment of atrial fibrillation. Manufacturers and doctors say patient enrollment in clinical studies is difficult because some patients that want ablation are unwilling to be assigned to groups that receive arrhythmia drugs instead. The advisory panel hearing also tackled the challenges faced in data gathering and interpretation of trial results.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY